dm+d

Unassigned

New Medicines

Sarcoma soft tissue, second-line

Information

New molecular entity
NantCell
NantCell

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

A tumor-targeted doxorubicin conjugate.
Soft tissue sarcoma is estimated to affect 3-4 in 10,000 people in the EU and US. About 50% of soft tissue sarcomas are found in the early stage and advanced stage patients have an average overall survival of 13 months.
Sarcoma soft tissue, second-line
Intravenous

Evidence based evaluations